News

ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide platform, for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) in hospitalized patients. RLS-0071 is the Company’s lead dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation and is currently in development for the treatment for hypoxic ischemic encephalopathy, acute graft-versus-host disease, and other rare and acute inflammatory diseases.

“The novel, dual mechanism-of-action of RLS-0071 that enables the rapid inhibition of both complement activation and neutrophil effectors (including myeloperoxidase, neutrophil elastase, and NETosis) holds great promise to address the fundamental drivers of the acute exacerbations that are a pervasive threat to COPD patients,” said ReAlta Chief Medical Officer Kenji Cunnion, MD, MPH. “With few effective options available today to address acute exacerbations, this study is an important step forward in developing an effective therapy for patients with AE-COPD.”

“With two Phase 2 trials now actively enrolling patients, ReAlta today reached another important milestone as we explore the potential for RLS-0071 across multiple therapeutic areas,” said ReAlta CEO Ulrich Thienel, MD, Ph.D. “AE-COPD is a disease with significant unmet need, threatening the lives and well-being of millions across the world, and burdening our healthcare systems with substantial economic costs. We believe RLS-0071 can have a significant role in addressing these problems.”

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial to evaluate safety, pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease. Approximately 24 hospitalized patients will receive doses of either RLS-0071 or placebo in addition to standard of care treatment for up to five days. The primary endpoint of the study is safety. Key secondary endpoints include biomarkers of inflammation, physiological response to RLS-0071 compared to placebo, as well as clinical progression and resolution. For more information about the study, please visit https://www.clinicaltrials.gov (NCT06175065).

 

Learn more here.

Recent News

09/16/2025

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly’s emerging bioconjugate platform and monoclonal antibody portfolio. Earlier

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures